Company profile
Aquestive Therapeutics, Inc.
NASDAQ: AQST · Healthcare · Drug Manufacturers - Specialty & Generic
#449 of 1,422 Healthcare companies by revenue27th-percentile growth
EA Score
47DFH 38DQ 56GM 48SS 62
v0.1 · 65/100 weight · provisional
↑ growth stability, market scale · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$50.3M
Rev growth YoY (TTM)
-7.3%
Net income (FY)
-$83.8M
Employees
147
as of 2026-08-12
Market cap
$553.3M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$44.5M$44.5M2025
Net income-$83.8M-$83.8M2025
Operating income-$71.1M-$71.1M2025
Total assets$160.4M$160.4M2025
Liabilities$194.1M$194.1M2025
Equity-$33.7M-$33.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Manufacture and Supply Revenue89%
License and Royalty Revenue8%
Co-Development and Research Fees3%
By geography
UNITED STATES66%
Non-US34%
The read
What is Aquestive Therapeutics, Inc.’s revenue?
Aquestive Therapeutics, Inc. booked $44.5M in FY2025 revenue, contracting 23% year over year — slower than 73% of Healthcare companies we track, at a -188.1% net margin.
Peers · Healthcare
TriSalus Life Sciences, Inc.44DPC Group, Inc.——Fennec Pharmaceuticals Inc.61CCumberland Pharmaceuticals Inc.70BNew York Health Care, Inc.——SANUWAVE Health Inc.74BNeighbors
Warren →Key facts
CEODaniel Barber
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersWarren, NJ
ExchangeNASDAQ: AQST
Employees147
IPO date2018-07-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.